Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?

  title={Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?},
  author={Fa{\"i}ez Zannad and Wendy Gattis Stough and Stuart J. Pocock and Peter J. Sleight and William C. Cushman and John G. F. Cleland and John J V McMurray and Eva M. Lonn and Nancy L. Geller and Hans Wedel and Eric C Abadie and Angeles Alonso-Garcia and Bertram Pitt},
  journal={European heart journal},
  volume={33 9},
Glycaemic control is an inadequate surrogate marker of cardiovascular event reduction in patients with type 2 diabetes. Clinical trials to date have been unsuccessful in identifying a therapeutic approach that addresses the underlying problem in diabetes (glycaemic control) and reduces cardiovascular risk. The potential for some agents to increase the risk of cardiovascular events has led to substantial changes in regulatory requirements for new anti-diabetic therapies. These requirements… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.


Publications citing this paper.
Showing 1-9 of 9 extracted citations

Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research • 2014
View 4 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 61 references

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

The New England journal of medicine • 2008
View 3 Excerpts
Highly Influenced

of Health

U. S. National Institute
http://clinicaltrials.gov 2011; Accessed 3/30/ • 2011
View 1 Excerpt

ACCORD and Risk-Factor Control in Type 2 Diabetes.

The New England journal of medicine • 2010

Similar Papers

Loading similar papers…